Chemical Financial Corporation operates as a financial holding company of Chemical Bank that offers a range of banking and fiduciary products and services to residents and business customers. It offers business and personal checking accounts, savings and individual retirement accounts, time deposit instruments, electronically accessed banking products, residential and commercial real estate financing, commercial lending, consumer financing, debit cards, safe deposit box, money transfer, automated teller machines, insurance and investment products, corporate and personal wealth management, and mortgage banking and other banking services. The company also offers mutual funds and annuities; trust, investment management, and custodial services; financial and estate planning; and retirement and employee benefit programs. As of December 31, 2018, it operated through 212 banking offices located in Michigan, northeast Ohio, and northern Indiana. The company has 8 loan production offices and approximately 237 automated teller machines. Chemical Financial Corporation was founded in 1917 and is headquartered in Detroit, Michigan.
Company Website : http://www.chemicalbank.com
Address : 333 Fort Street, Suite 100 48226,Detroit,USA
Employees : 3,117
Fiscal Year End : December
Currency: USD
Country : USA
Beta : 2.01
| Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
|---|---|---|---|---|---|
| LGCY | Legacy Reserves Inc |
N/A |
USD61,525,874.67B | 1.10 | 5.30 |
| FTD | FTD Companies, Inc |
N/A |
USD28,725,913.80B | N/A | N/A |
| KEYW | The KeyW Holding Corporation |
N/A |
USD24,651,104.38B | 166.80 | 24.48 |
| SNHY | Helios Technologies, Inc |
N/A |
USD17,848,852.22B | 1,000,000.00 | N/A |
| QTNA | Quantenna Communications, Inc |
N/A |
USD8,997,243.52B | 175.07 | 79.98 |
| INSY | INSYS Therapeutics, Inc |
N/A |
USD4,995,459.82B | 115.90 | N/A |
| CHKE | Apex Global Brands Inc |
N/A |
USD384,202.91B | 17.30 | N/A |
| AMCN | AirNet Technology Inc |
N/A |
USD308,457.30B | 1.00 | N/A |
| PDVW | pdvWireless, Inc |
N/A |
USD95,944.74B | N/A | N/A |
| AIPT | Predictive Oncology Inc |
N/A |
USD38,513.36B | N/A | N/A |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|
N/A
| Market Performance vs. Industry/Classification (Other) |
Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Trailing 12 Months | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Trailing 5 Years | |||||||
| Capital Gain | -11.26% | N/A | N/A | N/A | N/A | ||
| Dividend Return | 7.42% | N/A | N/A | N/A | N/A | ||
| Total Return | -3.83% | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -3.90% | N/A | N/A | N/A | N/A | ||
| Dividend Return | 1.39% | N/A | N/A | N/A | N/A | ||
| Total Return | -2.51% | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 15.35% | N/A | N/A | N/A | N/A | ||
| Risk Adjusted Return | -16.37% | N/A | N/A | N/A | N/A | ||
| Market Capitalization | 3.01B | N/A | N/A | N/A | N/A | ||
| Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
| A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
| B+ | 87%-89% | B | 83%-86% | B- | 80%-82% |
| C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
| D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
| F | 0%-59% |
| Ratio vs. Industry/Classification (Other) |
Ratio vs. Market |
||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| Market Value | |||||||
| Price / Earning Ratio | 10.98 | N/A | N/A | N/A | N/A | ||
| Price/Book Ratio | N/A | N/A | N/A | N/A | N/A | ||
| Price / Cash Flow Ratio | 9.27 | N/A | N/A | N/A | N/A | ||
| EV/EBITDA | N/A | N/A | N/A | N/A | N/A | ||
| Management Effectiveness | |||||||
| Return on Equity | N/A | N/A | N/A | N/A | N/A | ||
| Return on Invested Capital | 8.54% | N/A | N/A | N/A | N/A | ||
| Return on Assets | N/A | N/A | N/A | N/A | N/A | ||
| Debt to Equity Ratio | 15.02% | N/A | N/A | N/A | N/A | ||
| Technical Ratios | |||||||
| Short Ratio | N/A | N/A | N/A | N/A | N/A | ||
| Short Percent | N/A | N/A | N/A | N/A | N/A | ||
| Beta | 2.01 | N/A | N/A | N/A | N/A | ||
| Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
| A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
| B+ | 97%-89% | B | 83%-86% | B- | 80%-82% |
| C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
| D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
| F | 0%-59% |
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
No discussions yet
| User Name | Target Rating | Target Horizon (Months) | Target Price | User Analysis | Date | Comment |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company had positive total cash flow in the most recent four quarters.
There is nothing we particularly dislike
Do not have an account? Register here
